- $3.51bn
- $3.36bn
- $8.94bn
- 96
- 77
- 87
- 99
2019 September 28th | 2020 October 3rd | R2021 October 2nd | R2022 October 1st | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 52 W | 53 W | 52 W | 52 W | 52 W |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8,234 | 6,960 | 6,738 | 7,920 | 8,935 |
Cost of Revenue | |||||
Gross Profit | 592 | 526 | 526 | 622 | 743 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7,948 | 6,733 | 6,466 | 7,573 | 8,479 |
Operating Profit | 286 | 228 | 272 | 346 | 456 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 246 | 201 | 282 | 302 | 413 |
Provision for Income Taxes | |||||
Net Income After Taxes | 142 | 140 | 250 | 240 | 328 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 142 | 140 | 250 | 240 | 310 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 142 | 140 | 250 | 240 | 310 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.08 | 2.31 | 3.51 | 3.93 | 5.26 |